SLIDE 1
Firm Strategy and the Wealth of Regions Maryann P. Feldman - - PowerPoint PPT Presentation
Firm Strategy and the Wealth of Regions Maryann P. Feldman - - PowerPoint PPT Presentation
Firm Strategy and the Wealth of Regions Maryann P. Feldman University of North Carolina, Chapel Hill Ewing Marion Kauffman Motivation Questions of regional growth & viability Why some places grow and thrive? What factors are
SLIDE 2
SLIDE 3
Motivation
- Questions of regional growth & viability
– Why some places grow and thrive? – What factors are instrumental for new firm formation & growth?
- Need for more theoretical development
– Is Silicon Valley the archetype or one archetype? – Boulevard of Broken Dreams
- Appreciate theorizing
– Even our understanding of Silicon Valley evolves – Is Silicon Valley the archetype or one archetype
SLIDE 4
SLIDE 5
Route 128
SLIDE 6
Research Triangle Park
SLIDE 7
Proximity vs. Political Geography
SLIDE 8
I NNOVATIVE DATA SOURCES FOR REGIONAL ECONOMIC ANALYSIS
Maryann Feldman, Alex Graddy Reed, Lauren Lanahan, Glenn McLaurin, Kari Nelson, and Andrew Reamer
SLIDE 9
How do firms benefit from location?
SLIDE 10
How do firms benefit from location? How does location benefit from firm actions?
SLIDE 11
Porter’s Conceptualization of Strategy
- Limited to Competition
– Framework to understanding competition (1998:2) – Microeconomics-based approach to economic development useful government (1998:7)
- Nothing to inform cluster genesis
- Firm strategy notably absent
SLIDE 12
Constructed Locations
- Building a Cluster while Building a Firm
- The existence of knowledge spillovers implies
a subsidy
– Rent seeking – Capacity building
- Geography as a Platform for Innovation
SLIDE 13
The Concept of Corporate Strategy
“Corporate strategy is the pattern of decisions that …. defines the kind of economic and human
- rganization it is or intends to be and the nature
- f the economic and noneconomic contributions
it intends to make to its shareholders, employees, customers and communities.”
- - Andrews 2003: 52
SLIDE 14
The underappreciated role
- f firms in regions
- Enforcement of Non-Compete Agreements
– Gilson ,1999; Mars & Fleming ,2010
- Make or Buy Decisions/local
– Poppo and Zenger, 1998; Cassiman & Veugelers ,2006
- Philanthropic Contributions
– arts & culture – Gardberg & Fombrun ,2006 – infrastructure – Lowe & Feldman 2010
- Employment Conditions
– Stock options/Profit sharing – Educational Benefits – Skunkworks – Severance packages
SLIDE 15
Entrepreneurs as Organizational ByProducts
- Technical and product knowledge
– Agarwal et al., 2004; Chatterji, 2009; Sørensen and Phillips, 2011)
- Market related know-how
– Agarwal et al., 2004; Klepper and Sleeper, 2005
- Reputation and legitimacy signals
– Gulati and Higgins, 2003
- Ties to customers and suppliers
– Ferriani et al., 2012; Semadeni and Cannella, 2011
- Affiliations to financial and social capital
– Phillips, 2002; Burton, Sørensen and Beckman, 2002; Roberts, Klepper and Hayward, 2011
- Transfer Organizational Practices - HR practices rather than
Strategy
– Feldman, Reichstein & Ozran 2013
SLIDE 16
GlaxoSmithKline & its antecedents
Year Event NC Impact 1970 Burroughs Wellcome production facility moves to Greenville, North Carolina. +1,900 by 1995 1971 Burroughs Wellcome opens RTP research site + 339 employees 1971 +2,100 by 1995 1983 Glaxo Inc moves Headquarters to RTP & manufacturing to Zebulon +200 production jobs 1983 +3,000 by 1995 1995 Glaxo and Wellcome merge as Glaxo Wellcome.
- 1652 layoffs
- 535 early
retirements 1998 Glaxo Wellcome and Smith Kline Beecham enter into initial merger discussions (fails to materialize) High layoff predicted 2000 GlaxoSmithKline is formed through the merger of Glaxo Wellcome and SmithKline Beecham.
- 400 layoffs
2005 + Restructuring and the Great Recession
- Various layoffs
SLIDE 17
142 Glaxo/Burroughs Spawns
SLIDE 18
2 4 6 8 10 12 14 16 Number of Firms Started
New Firms Started with Links to GSK
Non-Merger Year Merger Year
Accidental Entrepreneurs -- fall or is pushed into an opportunity
SLIDE 19
2 4 6 8 10 12 14 16 18
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Number of Firms Started
Firms Started After Glaxo-Burroughs Wellcome and Glaxo Wellcome- SmithKline Beecham Mergers
Glaxo- Burroughs Wellcome Glaxo Wellcome- SmithKline Beecham
31 Firms 59 Firms
SLIDE 20
45% 26% 16% 10%
Merger 1: Glaxo-Burroughs Wellcome Drug Discovery & Medical Devices CROs Business Services ICT
Industry Sector for Glaxo-Burroughs Wellcome Spawns
- llars
SLIDE 21
45% 26% 16% 10%
Merger 1: Glaxo-Burroughs Wellcome
63% 15% 12% 10%
Merger 2: Glaxo Wellcome-SmithKline Beecham Drug Discovery & Medical Devices CROs Business Services ICT
White “Shirts” versus White “Coats”
SLIDE 22
13 GSK Spawns Founded 80% of 2nd Generation Spawns
13 39 90 49 10 20 30 40 50 60 70 80 90 100 GSK Spawns 2nd Generation Spawns Number of Firms Started
13 Leading Spinners 1. Lineberry Research Associates 2. DJ Pharma 3. Inspire Pharmaceuticals 4. ProviderLink 5. Cytospect Pharma 6. Healthmatics 7. Nuada Pharmaceuticals 8. Phase BioPharmaceuticals 9. Pozen, Inc. 10. SARCO 11. Triangle Pharmaceuticals 12. Victory Pharma 13. Zen-Bio
SLIDE 23
The Character of Place
- Business Strategy can build Prosperity
– Places & Regions are intertwined – Government can’t do it alone
- Investments in Place
– Sentimental? Altruistic? – Feasible for the long term for the private sector?
- New Logic of Economic Development
SLIDE 24